PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: RNCOS E-Services (P) Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Allovectin-7 to Enlarge Gene Therapy Revenue Patterns Finds RNCOS - Allovectin-7 (velimogene aliplasmid) is anticipated to generate estimated revenue worth US$ 400 Million in the US after its projected launch in 2012-2013, says RNCOS - RNCOS.com
Allovectin-7 to Enlarge Gene Therapy Revenue Patterns Finds RNCOS

 

NewswireToday - /newswire/ - Noida, Uttar Pradesh, India, 2012/04/16 - Allovectin-7 (velimogene aliplasmid) is anticipated to generate estimated revenue worth US$ 400 Million in the US after its projected launch in 2012-2013, says RNCOS - RNCOS.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

According to a new research offering by RNCOS,“Global Gene Therapy Market Analysis”, the global market for gene therapy has grown stupendously on the back of prominent factors, such as active private sector participation and impressive advancements in technologies. In fact, in less than a couple of decades, gene therapy has witnessed significant advancement as it progressed from the conceptual stage to the clinical trials stage in various indications. This, in turn, made the market attractive, thereby, boosting the sector to grow to the mark of US$ 485 Million by the end of 2011. In future, the market is likely to witness exceptional growth with the advent of new drugs in developed countries such as the US and Europe.

The report has found that Allovectin-7 (velimogene aliplasmid) is anticipated to generate estimated US$ 400 Million revenue in the US, after its projected launch in 2012-2013. AnGes MG has licensed rights to commercialize Allovectin-7 in several Asian countries, and is primarily interested in developing the same as a treatment for head and neck cancer. This indeed seems to meet a significant unmet medical need in Asia. Moreover, the Company expects to get the top line phase III results by the end of Q2 2012 for Allovectin-7 as first-line therapy in patients with Stage-III or -IV recurrent metastatic melanoma.

The report, spread over 115 pages, provides an extensive research and prudent analysis of the current status and expected position of the Global Gene Therapy Market. It provides comprehensive overview of the advanced gene therapy drugs along with recent industry developments to provide a balanced outlook on the market potential. Moreover, the report gives an effective insight into the gene therapy clinical trials that are being progressed in different phases of research and further analyzes the use of vectors in those studies.

The report is an outcome of an in-depth research of global gene therapy market that takes into accounts all the key industry developments and participants’ activities. It also investigates the current market trends and elaborates their market impact. The report facilitates the future forecasts on overall Gene Therapy Market size by 2015. Moreover, it projects the potential market to be generated by key gene therapy products to be launched in future. It analyzes the opportunity assessment for companies in the global gene therapy market in terms of key vectors and leading technologies.

Report/IM282

About RNCOS
RNCOS (rncos.com) specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: RNCOS E-Services (P) Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Allovectin-7 to Enlarge Gene Therapy Revenue Patterns Finds RNCOS

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Shushmul Maheshwari - RNCOS.com 
+91 12 04224700 press[.]rncos.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any RNCOS E-Services (P) Ltd securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From RNCOS E-Services (P) Ltd / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Xenex Receives Top Honors from Frost & Sullivan for LightStrike™ - the Only Pulsed Xenon UV Disinfection System in the Healthcare Market
Partners HealthCare and GE Healthcare Launch 10-year Collaboration to Integrate Artificial Intelligence into Every Aspect of the Patient Journey
US Acute Care Solutions Celebrates 2-Year Anniversary
GE Healthcare Receives FDA Indication Approval for Visipaque™ (iodixanol) Injection for use with Coronary CT Angiography
Telehealth Vendors Expand mHealth Portfolio to Conquer New Growth Opportunities Finds Frost & Sullivan
GE Healthcare Acquires Asymptote for Complete, Digitally-enabled Cryogenic Cold Chain Technology Supporting Safe Manufacture And Delivery Of Cellular
ANVISA Approval for EMCM Facilitates the Progress of Leader Biomedical Operations in Brazil
GE Healthcare Expands Digital Maternal-Infant Care Offerings with Acquisition of Monica Healthcare
Next-generation Natural Materials to Replace Traditional Synthetic Materials in Personal Care Products Finds Frost & Sullivan
Digital Innovation-driven Diagnostic Advances Transform Smart Healthcare Finds Frost & Sullivan
Hospitals’ Outsourcing of Sterile Processing Expand Opportunities for Third Party Service Providers in the US & Western Europe Finds Frost & Sullivan
Emerging Cardiac Therapies Catalysed by Innovative Product and Next-generation Technology Finds Frost & Sullivan
Austrian Centre of Industrial Biotechnology and GE Healthcare Establish A Cell Line Engineering Collaboration
Sequencing Platform Providers Aim to Develop Tests for Infectious Diseases to Expand Market Opportunity Finds Frost & Sullivan
Arcadia Wins Top Honors from Frost & Sullivan for its Next-generation Clinical and Claims Analytics Platform, Arcadia Analytics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  Deb Sheppard - Medium Psychic Author Speaker





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)